Anti-PD-1 data suggest similar activity in squamous and nonsquamous NSCLC
Patient characteristics were similar in both studies
CheckMate 057: nonsquamous
1
HR = 0.73 (96% CI: 0.59, 0.89)
P
= 0.0015
Nivolumab
Docetaxel
1-yr OS rate = 51%
1-yr OS rate = 39%
OS (%)
Time (months)
100
90
80
70
60
50
40
30
10
0
20
27
21
18
15
12
9
6
3
0
24
CheckMate 017: squamous
2
HR = 0.62 (0.48, 0.81);
P
= 0.0004
Nivolumab
Docetaxel
1-yr OS rate = 42%
1-yr OS rate = 24%
OS (%)
Time (months)
100
90
80
70
60
50
40
30
10
0
20
33
21
18
15
12
9
6
3
0
27
30
24
Histology
Borghaei H et al NEJM 2015; Brahmer J NEJM 2015
Nivolumab
(n=292)
Docetaxel
(n=290)
HR
Median OS, months
12.2
9.4
HR = 0.73 (96% CI: 0.59, 0.89);
P
=
0.0015
Median PFS, months
2.3
4.2
HR = 0.92 (95% CI: 0.77, 1.11);
P
=
0.3932
ORR, %
19
12
P
= 0.0246
Median DOR,
months
17.2
5.6
Nivolumab
(n=135)
Docetaxel
(n=137)
HR
Median OS, months
9.2
6.0
HR = 0.62 (0.48, 0.81);
P
=
0.0004
Median PFS,
months
3.5
2.8
HR = 0.63 (0.48, 0.83);
P
=
0.0008
ORR, %
20
9
P
= 0.008
Median DOR,
months
NR
8.4
